Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control

Background Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carci...

Full description

Saved in:
Bibliographic Details
Main Authors: Renee N Donahue, Jeffrey Schlom, James L Gulley, Claudia Palena, Duane H Hamilton, Masafumi Iida, Maria del Mar Maldonado, Maria Gracia-Hernandez, Loc Huu Le
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011378.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items